Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Novo Nordisk's oral Wegovy formulation has surpassed 5 million prescriptions since launch, signaling strong market uptake. Real-world studies presented at the Liver Meeting (AASLD 2026) link semaglutide 2.4 mg weekly injections to statistically significant mean weight loss of 18.9 pounds (8.6 kg) from baseline in adults with MASH, alongside reductions in liver enzymes and blood sugar. However, a Daily Mail report indicates some patients switching from injectable GLP-1s to the Wegovy pill experienced weight regain. Medicare's new GLP-1 Bridge pilot program, capping monthly costs at $50 for eligible seniors, continues to drive adoption. ObesityWeek 2026 in Washington, D.C., will feature further effectiveness and dosing data.
Listen to Live Briefing
Real-time synthesized voice briefing ยท Live Feeds Desk
- โ Novo Nordisk's Wegovy pill has surpassed 5 million prescriptions since launch.
- โ Real-world studies PLATINUM-Truveta and RHODIUM-2 link semaglutide 2.4 mg weekly injection to statistically significant mean weight loss of 18.9 pounds (8.6 kg) from baseline in adults with MASH.
- โ Medicare's GLP-1 Bridge pilot program caps monthly costs at $50 for eligible seniors.
- โ ObesityWeek 2026 in Washington, D.C., will present comprehensive effectiveness, side effect, and dosing data for Wegovy formulations.
What changed
Wegovy pill prescriptions topped 5 million; new AASLD real-world data confirms injectable semaglutide 2.4 mg benefits for MASH; Daily Mail reports weight regain in some patients switching from shots to pill.
Live updates
-
Wegovy pill hits 5M prescriptions as real-world data shows mixed switching results
Novo Nordisk's oral Wegovy formulation has surpassed 5 million prescriptions since launch, signaling strong market uptake. Real-world studies presented at the Liver Meeting (AASLD 2026) link semaglutide 2.4 mg weekly injections to statistically significant mean weight loss of 18.9 pounds (8.6 kg) from baseline in adults with MASH, alongside reductions in liver enzymes and blood sugar. However, a Daily Mail report indicates some patients switching from injectable GLP-1s to the Wegovy pill experienced weight regain. Medicare's new GLP-1 Bridge pilot program, capping monthly costs at $50 for eligible seniors, continues to drive adoption. ObesityWeek 2026 in Washington, D.C., will feature further effectiveness and dosing data.
Why it matters
The Wegovy pill represents Novo Nordisk's shift toward a volume-driven oral obesity franchise after years of injectable dominance. Strong prescription volumes and Medicare coverage expansion suggest commercial momentum, but real-world switching outcomes appear variable. The AASLD data reinforces injectable semaglutide's metabolic benefits in MASH patients, while anecdotal reports of weight regain after switching to oral formulation raise questions about dose equivalence and adherence. Upcoming ObesityWeek presentations will clarify comparative effectiveness.
What is confirmed
- Novo Nordisk's Wegovy pill has surpassed 5 million prescriptions since launch.
- Real-world studies PLATINUM-Truveta and RHODIUM-2 link semaglutide 2.4 mg weekly injection to statistically significant mean weight loss of 18.9 pounds (8.6 kg) from baseline in adults with MASH.
- Medicare's GLP-1 Bridge pilot program caps monthly costs at $50 for eligible seniors.
- ObesityWeek 2026 in Washington, D.C., will present comprehensive effectiveness, side effect, and dosing data for Wegovy formulations.
Still unconfirmed
- Some patients switching from injectable GLP-1s to the Wegovy pill have experienced weight regain, according to a Daily Mail report.
What to watch next
- ObesityWeek 2026 presentations on comparative effectiveness of oral vs. injectable Wegovy
- FDA or EMA guidance on dose equivalence between oral and injectable semaglutide
- Medicare GLP-1 Bridge program enrollment and cost data for Q4 2026
confidence 75%Sources used for this update (16)
- www.fool.com โ Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?
- ground.news โ Two men charged in $120M adult day care fraud scheme in Queens
- ground.news โ Patient lived with world's first pig kidney transplant for nine...
- ground.news โ โLit Me upโ: Patient Recalls Alleged Hospital Attack
- ground.news โ Hospitals agree to halt gender-affirming care for transgender...
- ground.news โ Former Patient Sues Sen. Roger Marshall Over Alleged Illegal...
- ground.news โ GOP Sen. Roger Marshall Sued More Than 700 Patients Over Medical...
- ground.news โ GLP-1 Makers Sued Over Rare Sudden Vision Loss - Ground News
- ground.news โ 'You saw nothing': aged care nurse assaulted six patients in...
- ground.news โ Talk to teen patients about dating violence, Canadian Paediatric...
- ground.news โ First Ebola patients in Nigeria and Kenya might have crossed...
- www.prnewswire.com โ Novo real-world studies link Wegovyยฎ 2.4 mg to reductions in ...
-
Wegovy Pill Sales Surge as ObesityWeek Prepares New Data
Patients transitioning to Novo Nordisk's oral Wegovy formulation from injectable treatments achieve greater weight reduction, according to real-world findings slated for presentation. Concurrently, commercial metrics show strong market uptake. Sales for the Wegovy pill jumped 53 percent in the third quarter of 2026 to reach approximately $811 million, outperforming analyst estimates by 17 percent. This financial expansion is driven significantly by Medicare's new GLP-1 Bridge pilot program, which caps monthly expenses at $50 for eligible seniors. Meanwhile, the broader medical community prepares to examine comprehensive effectiveness, side effect profiles, and dosing data as ObesityWeek 2026 approaches in Washington, D.C.
Why it matters
GLP-1 medications historically functioned strictly as weekly injections, making the oral formulation a major shift in delivery mechanisms for weight management. National tracking indicates that nearly 149,000 Americans initiated oral semaglutide during a 12-week span in 2026. As adoption scales globally through markets including the United Kingdom and Australia, health authorities continue to monitor pricing structures and caution against unauthorized online purchases.
What is confirmed
- Wegovy pill sales surged 53% in Q3 2026 to approximately $811 million.
- Novo Nordisk announced plans to present 26 abstracts at ObesityWeek 2026.
- ObesityWeek 2026 takes place from November 14 to November 17 in Washington, D.C.
- Medicare's new GLP-1 Bridge pilot program capped monthly costs at $50 for eligible seniors.
Still unconfirmed
- Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study.
What to watch next
- Presentation of the 26 abstracts at ObesityWeek 2026 from November 14 to November 17.
- Further data regarding telehealth treatment experiences and the CagriSema REDEFINE program.
confidence 100%Sources used for this update (6)
- www.marketscreener.com โ Novo Nordisk Announces Presentation Of New CagriSema And ...
- cnalifestyle.channelnewsasia.com โ Wegovy weight-loss pills vs injections: How do they compare ...
- healthfactsjournal.com โ Wegovy Pill: Effectiveness, Cost, Side Effects & More
- theconversation.com โ Australia is set to get a Wegovy pill. How does it compare ...
- www.techtimes.com โ Wegovy Pill Outperforms Foundayo as Medicare Drives Novo's ...
- www.hemed.com โ Wegovy (semaglutide) | HeMed
-
Novo Nordisk to Present Real-World Wegovy Data at ObesityWeek
Nearly 149,000 Americans started oral semaglutide during a 12-week period in 2026, according to national data tracking the fast start of the Wegovy pill. Novo Nordisk announced plans to present 26 abstracts at ObesityWeek 2026, which runs from November 14 to November 17 in Washington, D.C. These upcoming presentations will feature real-world treatment experiences with both the Wegovy pill and injection, including data gathered from telehealth environments. Additional presentations will cover analyses from the CagriSema REDEFINE program and research involving semaglutide injections in children.
Why it matters
Real-world data on oral semaglutide uptake provides vital visibility into how patients adopt weight-loss medications outside of controlled clinical trials. Novo Nordisk is set to showcase these findings alongside broader portfolio research during the upcoming ObesityWeek conference. This evaluation helps medical professionals understand shifting patient preferences between oral treatments and traditional injections.
What is confirmed
- Nearly 149,000 Americans started oral semaglutide over a 12-week period in 2026.
- Novo Nordisk will present new data from its obesity portfolio across 26 abstracts at ObesityWeek 2026 in Washington, D.C., from November 14 to November 17.
- The upcoming ObesityWeek presentations include real-world treatment experience data for the Wegovy pill and injection from telehealth settings.
- Novo Nordisk will also present new analyses from the investigational CagriSema REDEFINE program and research on semaglutide injection in children ages 6 to under 12.
What to watch next
- Presentation of detailed real-world Wegovy pill data at ObesityWeek 2026 between November 14 and November 17.
- Release of further findings from the CagriSema REDEFINE program.
confidence 100%Sources used for this update (7)
- www.novonordisk.com โ Press releases - Novo Nordisk
- joeymed.com โ The Wegovy Pill's Fast Start in 2026: What New Data on ...
- ctv.veeva.com โ A Two-year Prospective, Observational Study of Wegovy in Real ...
- www.prnewswire.com โ Novo to present new CagriSema and Wegovyยฎ data at ObesityWeek ...
- www.biospace.com โ Novo to present new CagriSema and Wegovyยฎ data at ... - BioSpace
- finance.yahoo.com โ Novo to present new CagriSema and Wegovyยฎ data at ObesityWeek ...
- healthfactsjournal.com โ Wegovy weight loss: Options, Effectiveness, Costs & Safety ...
-
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight
A real-world study found patients switching from Wegovy injections to the pill lost more weight. The oral version of Wegovy achieved 15% to 17% weight loss over 68 weeks in the phase 3 OASIS 1 trial. Patients switching from injections to the pill lost an additional 4.1% of body weight over three months.
Why it matters
The developments target the growing obesity market rivalry with Eli Lilly. Novo Nordisk's Wegovy pill and injection are used for weight loss. The company also released analysis indicating its experimental CagriSema injection outperforms Wegovy.
What is confirmed
- The oral version of Wegovy achieved 15% to 17% weight loss over 68 weeks in the phase 3 OASIS 1 trial.
- Patients switching from injections to the pill lost an additional 4.1% of body weight over three months.
- Novo Nordisk's experimental CagriSema injection shows 25% weight loss in women.
- Oral semaglutide initiation climbed quickly after its December 2025 FDA approval among nearly 48 million US adults eligible for obesity medications.
What to watch next
- Novo Nordisk's CagriSema injection trial results
- Eli Lilly's response to Wegovy and CagriSema
- Wegovy pill and injection price changes
confidence 100%Sources used for this update (4)
- www.biospace.com โ Obesity - BioSpace
- www.ajmc.com โ Oral Semaglutide Uptake Near Injectable Levels Within 3 ...
- creators.yahoo.com โ Wegovy pill or Wegovy shot? A doctor explains how they ...
- www.treatmentshub.com โ GLP-1 Pills vs Injections (2026): Results, Cost & Routine
-
Novo Nordisk reports oral Wegovy and CagriSema weight loss results
Novo Nordisk's 50 mg once-daily oral version of Wegovy achieved 15% to 17% weight loss over 68 weeks in the phase 3 OASIS 1 trial, matching the efficacy of the weekly injection. This follows separate data showing patients switching from injections to the pill lost an additional 4.1% of body weight over three months. Simultaneously, the company released analysis indicating its experimental CagriSema injection outperforms Wegovy, specifically showing 25% weight loss in women. These developments target the growing obesity market rivalry with Eli Lilly.
Why it matters
Novo Nordisk already sells Rybelsus, a lower-dose oral GLP-1 agonist for type 2 diabetes that earned approximately $1.7 billion last year. The shift toward oral formulations and high-potency injections aims to maintain market share as competitors like Eli Lilly release Foundayo.
What is confirmed
- A 50 mg once-daily oral dose of semaglutide resulted in 15% to 17% weight loss over 68 weeks in the OASIS 1 study.
- The weight loss from the 50 mg oral dose aligns with results from the weekly Wegovy injection at the 68-week mark.
- Rybelsus, a lower-dose oral GLP-1 agonist for type 2 diabetes, had sales of around $1.7 billion last year.
Still unconfirmed
- The experimental CagriSema injection showed 25% weight loss in women.
- Patients switching from weekly injections to the Wegovy pill lost an average of an additional 4.1% of body weight over three months.
What to watch next
- Regulatory approval timelines for the 50 mg oral Wegovy dose
- Full clinical trial data for the CagriSema injection across all demographics
confidence 90%Sources used for this update (2)
- pharmaphorum.com โ Novo Nordisk says oral Wegovy hits weight loss goal
- www.cnbc.com โ Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
-
Wegovy pill users lose additional weight after switching from injections
Patients transitioning from weekly injections to the Wegovy pill lost an average of an additional 4.1% of their body weight over three months. Novo Nordisk presented this data from 194 participants at the 2026 European Association for the Study of Diabetes meeting. The results suggest patients can maintain or increase weight loss while moving to an oral format. This development occurs as competition intensifies with Eli Lilly's Foundayo and as major employers like Walmart expand coverage for diabetes treatments including Ozempic and Mounjaro.
Why it matters
Oral GLP-1 medications aim to increase patient persistence by replacing needles with pills. While efficacy remains high, researchers are targeting a reduction in gastrointestinal side effects. Physicians have also raised concerns regarding bone quality during rapid weight loss.
What is confirmed
- 194 people who switched from weekly injections to the Wegovy pill lost an average of an additional 4.1% of body weight over three months.
- Novo Nordisk presented the switching data at the 2026 European Association for the Study of Diabetes meeting.
- Walmart plans to cover over 250 prescription medications at no cost for its workforce, including Ozempic and Mounjaro for employees with Type 2 diabetes.
Still unconfirmed
- US prices for GLP-1 pills start from $149 a month in 2026.
What to watch next
- Market adoption rates for Foundayo compared to the Wegovy pill.
confidence 90%Sources used for this update (4)
- belite.com โ Switching From Wegovy or Zepbound Injections to the Wegovy ...
- www.cafepharma.com โ Novo Nordisk | Cafepharma
- www.drugwatch.com โ Wegovy (Semaglutide): Uses, Side Effects & FDA Overview
- www.strategicrevenueinsights.com โ GLP-1 Pills vs Injections: 2026 Results, Dosing, Prices
-
Novo Nordisk Highlights Oral Wegovy Data Amid Rival Pressure
Adults with overweight or obesity who transition from injectable GLP-1 medications to the once-daily oral semaglutide pill, known as Wegovy, lose an average of 4.1 percent of their body weight, or 8.8 pounds, after three months. Presented at the EASD conference in Milan, the OCTANE analysis shows patients can move away from weekly injections without sacrificing weight reduction. Meanwhile, rival Eli Lilly reports accelerating prescription growth for its oral option, Foundayo, intensifying competition in the oral weight-loss market as Novo Nordisk works to strengthen its position.
Why it matters
Novo Nordisk is releasing new real-world data following weaker sales growth for its injectable GLP-1 drugs. The company partnered with Ro to gather additional evidence and showcased cardiovascular and liver-fat data in Milan. At the same time, Novo Nordisk added a new weekly oral option to its early pipeline through a partnership with China's Hengrui Pharma.
What is confirmed
- Adults with overweight or obesity who switched from an injectable GLP-1 medicine to once-daily oral semaglutide lost an average of 4.1 percent of their body weight, or 8.8 lbs, after three months on treatment.
- The OCTANE analysis was presented at the EASD conference in Milan.
- Eli Lilly's oral GLP-1 receptor agonist Foundayo saw total prescriptions surge about 21 percent to 64,268 during the previous week, according to IQVIA data cited by Citi.
Still unconfirmed
- The OCTANE study analysis was retrospective, weights were self-reported, and the results have not been peer-reviewed.
What to watch next
- Peer review and publication status of the OCTANE study data
- Further prescription tracking data for Eli Lilly's Foundayo versus oral Wegovy
- Development progress on the early pipeline option from the Hengrui Pharma partnership
confidence 95%Sources used for this update (5)
- pharmaphorum.com โ Novo Nordisk fights back with oral GLP-1 data in obesity
- www.cafepharma.com โ Novo Nordisk | Cafepharma
- www.marketscreener.com โ News Novo Nordisk A/S
- www.thepeptidenewsroom.com โ Wegovy Pill Showed 4.1% Further Weight Loss After Switching ...
- pharmaphorum.com โ Novo, Lilly trade oral GLP-1 data readouts at ECO
-
Oral Semaglutide Switch Shows 4.1% Weight Loss at 3 Months
Adults with overweight or obesity who transition from injectable GLP-1 medications to the once-daily oral semaglutide pill lose an average of 4.1 percent of their body weight after three months. Observational findings from the OCTANE analysis, presented at the EASD 2026 conference, indicate that patients can move away from weekly injections toward a convenient daily treatment without sacrificing weight reduction. Novo Nordisk also partnered with Ro to gather additional real-world evidence for the oral medication while showcasing cardiovascular and liver-fat data in Milan.
Why it matters
The OCTANE analysis addresses the growing clinical interest in whether patients can successfully maintain or improve weight loss outcomes after moving from injectable therapies to daily pills. This observational data provides early insight into alternative administration routes for semaglutide outside of controlled clinical trials. Novo Nordisk continues to build an evidence base for the oral formulation through partnerships and ongoing presentations of metabolic and cardiovascular metrics.
What is confirmed
- Adults switching from injectable GLP-1 treatments to once-daily oral semaglutide shed an average of 4.1 percent of their body weight after three months.
- Findings from the OCTANE real-world analysis were presented at the EASD 2026 conference.
Still unconfirmed
- The observational study lacked a comparator group.
What to watch next
- Additional real-world evidence generated through the Novo Nordisk and Ro research collaboration
- Further data releases regarding liver-fat and cardiovascular outcomes from ongoing meetings
confidence 100%Sources used for this update (4)
- www.patientcareonline.com โ Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
- www.universityhealth.com โ For Patients | San Antonio | University Health
- uthealthsahospital.org โ MyChart Patient Portal | Multispecialty and Research Hospital ...
- www.universityhealth.com โ Information For Patients And Visitors | San Antonio ...
-
Wegovy Pill Shows Weight Loss in Real-World Study
Adults with overweight or obesity who transitioned from injectable GLP-1 treatments to once-daily oral semaglutide, known as the Wegovy pill, shed an average of 4.1 percent of their body weight after three months. Findings from the OCTANE real-world analysis were presented at the EASD 2026 conference. The results suggest patients may not require lifelong weekly injections and can instead utilize more convenient daily oral treatments. Novo Nordisk also announced a research collaboration with Ro to generate additional real-world evidence for the oral medication, while continuing to present liver-fat and cardiovascular data at the meeting in Milan.
Why it matters
The data arrive as drugmakers race to capture market share in the rapidly expanding obesity treatment sector. Novo Nordisk is leaning heavily on oral GLP-1 therapies to bolster growth amid a 24 percent stock slide this year and intense competition from rivals like Eli Lilly. Understanding whether daily pills can maintain or improve weight loss outcomes after injections offers critical direction for long-term patient care strategies.
What is confirmed
- Adults with overweight or obesity who switched from injectable GLP-1 medicines to once-daily oral semaglutide, marketed as the Wegovy pill, lost an average of 4.1 percent of their body weight over three months.
- The findings were presented as part of the real-world OCTANE analysis at the EASD 2026 conference.
- Novo Nordisk and Ro announced a research collaboration to generate real-world evidence on the Wegovy pill.
What to watch next
- Further real-world data releases from the Novo Nordisk and Ro research collaboration.
- Additional long-term weight loss and adherence metrics for patients using oral semaglutide.
confidence 100%Sources used for this update (19)
- Reuters โ Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
- CNBC โ People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
- qz.com โ Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds
- PR Newswire โ Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovyยฎ Pill
- The Pharma Letter โ Real-world study shows continued weight loss after switching to oral Wegovy
- www.ad-hoc-news.de โ Novo Nordisk Cuts Wegovy Price in Sweden While Ozempic Data Bests Mounjaro
- www.ad-hoc-news.de โ Novo Nordisk Touts Liver-Fat and Cardiovascular Data as It Battles a 24% Slide
- www.devdiscourse.com โ Reuters Health News Summary
- www.cnbc.com โ Novo's Wegovy pill improves weight loss after switch from ...
- health.yahoo.com โ Novo Nordisk Study Reports Weight Loss After Patients Switch ...
- www.prnewswire.com โ People switching from weight-loss injections to Novo's Wegovy ...
- www.biopharminternational.com โ Wegovy Pill Delivers 4.1% Weight Loss in Patients Switching ...
Community Sentiment: How do you assess this situation?
Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community